NEW YORK (GenomeWeb) – Israeli epigenetics-based diagnostics firm Nucleix announced on Monday that it has raised more than $5 million in private financing.
The company's lead product is the urine-based Bladder EpiCheck for detecting bladder cancer. The funding will go toward clinical trials for the test, as well as efforts to gain European CE marking and US Food and Drug Administration regulatory approval, Tel Aviv, Israel-based Nucleix said. Funds will also be used to develop diagnostic tests for other cancers.
OrbiMed invested more than $4 million in the funding round, while entrepreneur and private investor Zohar Zisapel and angel investors also participated in the raise. It is the first time Nucleix has raised funding from a venture capital fund since being founded in 2008, it said.
The company also appointed Opher Shapira as president and COO. Shapira was a founder of cancer screening firm BioView, where he also served as president and CEO.